Nanobiotix: Differentiated Radiotherapy Enhancer, J&J Partnership, and Multi-Indication Pipeline Undervalue Long-Term Upside, Supporting Buy Rating

Nanobiotix (NBTX) has received a new Buy rating, initiated by TD Cowen analyst, Tara Bancroft.

Tara Bancroft has given his Buy rating due to a combination of factors tied to Nanobiotix’s differentiated technology and commercial potential. He highlights that NBTXR3 is a physics-based, tumor-agnostic nanoparticle that markedly boosts the effect of radiotherapy without adding meaningful toxicity, addressing a very large global patient population that receives radiation each year. Early clinical evidence is cited as compelling, including Phase I data in locally advanced head and neck cancer showing a meaningful improvement in median overall survival versus historical benchmarks, with a pivotal Phase III trial in collaboration with Johnson & Johnson expected to reinforce these findings. Bancroft also notes that interim data from key studies, including in cisplatin-ineligible and cisplatin-eligible patient segments, could significantly expand the addressable market and validate the product’s use across broader settings.

Furthermore, he underscores the importance of the strategic partnership with Johnson & Johnson as external validation of NBTXR3’s clinical and commercial value and as a driver of substantial prospective royalty income. His model anticipates robust peak sales from the lead indication, translating into meaningful royalty revenue for Nanobiotix by the mid-2030s. Bancroft also sees an additional, sizable opportunity in locally advanced non–small cell lung cancer, where a Phase III program and forthcoming Phase II data could support another multi-billion-euro revenue stream. Finally, he points to optionality from additional tumor types and from the company’s Curadigm and OOcuity platforms, which together create a diversified pipeline and support his view that the current valuation does not fully reflect the long-term upside, justifying a Buy recommendation.